References
Balwani M (2019) Erythropoietic protoporphyria and X-linked protoporphyria: pathophysiology, genetics, clinical manifestations, and management. Mol Genet Metab 128(3):298–303. https://doi.org/10.1016/j.ymgme.2019.01.020
Meerman L (2000) Erythropoietic protoporphyria. An overview with emphasis on the liver. Scand J Gastroenterol Suppl 232:79–85
Shirota T, Yamamoto H, Hayashi S et al (2000) Myelodysplastic syndrome terminating in erythropoietic protoporphyria after 15 years of aplastic anemia. Int J Hematol 72(1):44–47
Casanova-González MJ, Trapero-Marugán M, Jones EA et al (2010) Liver disease and erythropoietic protoporphyria: a concise review. World J Gastroenterol 16(36):4526–4531. https://doi.org/10.3748/wjg.v16.i36.4526
Ardalan ZS, Chandran S, Vasudevan A et al (2019) Management of patients with erythropoietic protoporphyria-related progressive liver disease. Liver Transpl 25(11):1620–1633. https://doi.org/10.1002/lt.25632
Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129(11):1428–1436. https://doi.org/10.1182/blood-2016-08-693481
Gilreath J, Lo M, Bubalo J (2021) Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs 81(11):1285–1305. https://doi.org/10.1007/s40265-021-01553-7
Drexler B, Passweg J (2021) Current evidence and the emerging role of eltrombopag in severe aplastic anemia. Ther Adv Hematol 12:2040620721998126. https://doi.org/10.1177/2040620721998126
Acknowledgements
We thank the families for giving consent to disclose their medical records and provide blood samples for our study.
Funding
The work was supported by the National Natural Science Foundation of China (NSFC) (81970106).
Author information
Authors and Affiliations
Contributions
Z.J. and M.C. provided diagnosis and treatment for the patient and wrote the manuscript. Both authors reviewed the manuscript and approved the final submission of the manuscript.
Corresponding author
Ethics declarations
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare no competing interests.
Informed consent
Informed consent was obtained from the patient included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jiang, Z., Jiang, X. & Chen, M. Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag. Ann Hematol 101, 1361–1363 (2022). https://doi.org/10.1007/s00277-021-04726-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04726-2